Global Meloxicam Drug Market, Size, Share and Trends Analysis Report, By Disease Indication (Osteoarthritis, Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy),Forecast (2022-2028).

The global Meloxicam drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Meloxicam is a prescription drug used to treat the symptoms of osteoarthritis and arthritis in adults and it may also be prescribed to relieve arthritis-related pain in children at least 2 years of age. Meloxicam belongs to a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). The increasing popularity of these drugs over other opioid-like painkillers is contributing to its market growth. In addition, the increase in chronic inflammatory diseases and pains are the factors that are focused on the market growth. However, the adverse effects of meloxicam drugs such as sores, dizziness, and so on may affect the global market for meloxicam drug market.

Teva Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories, Lupin Ltd., and Apotex Corp,are the kay market players that are making significant contribution to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches. For instance, in December 2020, Lupine NSE -0.36% had introduced the meloxicam pills, for used to treat osteoarthritis (OA) pain, and in the US market, the company launched the product after receiving approval from the US FDA.

Further in, 7^thApril 2020,Baudax Bio, Inc., announced the ANJESO (meloxicam), the only 24-hour, intravenous (IV) COX-2 preferential non-steroidal drug. It is an anti-inflammatory drug, that is now available for order and delivery and ANJESO was approved by the US FDA on February 20, 2020, it has been shown to treat moderate to severe pain, alone or in combination with other non-NSAID analgesics.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Disease Indication
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Sun Pharmaceutical Inc.Ltd., Teva Pharmaceutical Inc. Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Ltd., and Apotex Corp., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Meloxicam Drug Market Report by Segment

By Disease

• Osteoarthritis
• Rheumatoid Arthritis
• Juvenile Rheumatoid Arthritis
• Others

By Distribution Channel

• Direct Tender
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Meloxicam Drug Market Report by Region

North America

• US
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa